NovaDel Pharma Inc.
Condensed Statements of Operations
(Unaudited)
| |
|
Three Months Ended June 30,
|
|
|
Six Months Ended June 30,
|
|
| |
|
2011
|
|
|
2010
|
|
|
2011
|
|
|
2010
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties
|
|
$ |
127,000 |
|
|
$ |
— |
|
|
$ |
127,000 |
|
|
$ |
— |
|
|
Milestone fees
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
62,000 |
|
|
License fees
|
|
|
65,000 |
|
|
|
66,000 |
|
|
|
130,000 |
|
|
|
133,000 |
|
|
Total revenue
|
|
|
192,000 |
|
|
|
66,000 |
|
|
|
257,000 |
|
|
|
195,000 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
412,000 |
|
|
|
559,000 |
|
|
|
1,032,000 |
|
|
|
1,006,000 |
|
|
General and administrative
|
|
|
703,000 |
|
|
|
813,000 |
|
|
|
1,385,000 |
|
|
|
1,787,000 |
|
|
Total operating expenses
|
|
|
1,115,000 |
|
|
|
1,372,000 |
|
|
|
2,417,000 |
|
|
|
2,793,000 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(923,000 |
) |
|
|
(1,306,000 |
) |
|
|
(2,160,000 |
) |
|
|
(2,598,000 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in derivative liability
|
|
|
(2,427,000 |
) |
|
|
181,000 |
|
|
|
3,684,000 |
|
|
|
181,000 |
|
|
Change in conversion feature liability
|
|
|
(794,000 |
) |
|
|
— |
|
|
|
27,000 |
|
|
|
— |
|
|
Interest expense
|
|
|
(875,000 |
|
|
|
(1,000 |
) |
|
|
(9,148,000 |
) |
|
|
(1,000 |
) |
|
Total other income (expense)
|
|
|
(4,096,000 |
) |
|
|
180,000 |
|
|
|
(5,437,000 |
) |
|
|
180,000 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(5,019,000 |
) |
|
$ |
(1,126,000 |
) |
|
$ |
(7,597,000 |
) |
|
$ |
(2,418,000 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss per common share
|
|
$ |
(0.04 |
) |
|
$ |
(0.01 |
) |
|
$ |
(0.07 |
) |
|
|
(0.03 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding – basic and diluted
|
|
|
129,080,346 |
|
|
|
97,918,458 |
|
|
|
115,961,695 |
|
|
$ |
93,194,701 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|